RU2684112C2 - Комбинированная терапия для лечения нозокомиальной пневмонии - Google Patents

Комбинированная терапия для лечения нозокомиальной пневмонии Download PDF

Info

Publication number
RU2684112C2
RU2684112C2 RU2015132369A RU2015132369A RU2684112C2 RU 2684112 C2 RU2684112 C2 RU 2684112C2 RU 2015132369 A RU2015132369 A RU 2015132369A RU 2015132369 A RU2015132369 A RU 2015132369A RU 2684112 C2 RU2684112 C2 RU 2684112C2
Authority
RU
Russia
Prior art keywords
ceftazidime
avibactam
hours
mic
combination
Prior art date
Application number
RU2015132369A
Other languages
English (en)
Russian (ru)
Other versions
RU2015132369A (ru
Inventor
Шампа ДАС
Цзяньго ЛИ
Йохан Виллем МАУТОН
Райт НИКОЛС
Original Assignee
Пфайзер Анти-Инфективз Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50114393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2684112(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пфайзер Анти-Инфективз Аб filed Critical Пфайзер Анти-Инфективз Аб
Publication of RU2015132369A publication Critical patent/RU2015132369A/ru
Application granted granted Critical
Publication of RU2684112C2 publication Critical patent/RU2684112C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2015132369A 2013-02-06 2014-02-06 Комбинированная терапия для лечения нозокомиальной пневмонии RU2684112C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361761369P 2013-02-06 2013-02-06
US61/761,369 2013-02-06
PCT/GB2014/050354 WO2014122468A1 (en) 2013-02-06 2014-02-06 Combination therapy for the treatment of nosocomial pneumonia

Publications (2)

Publication Number Publication Date
RU2015132369A RU2015132369A (ru) 2017-03-13
RU2684112C2 true RU2684112C2 (ru) 2019-04-04

Family

ID=50114393

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015132369A RU2684112C2 (ru) 2013-02-06 2014-02-06 Комбинированная терапия для лечения нозокомиальной пневмонии

Country Status (13)

Country Link
US (1) US20150374673A1 (enExample)
EP (1) EP2953626A1 (enExample)
JP (1) JP6383367B2 (enExample)
KR (1) KR20150115761A (enExample)
CN (2) CN104994860A (enExample)
AU (1) AU2014213795B2 (enExample)
BR (1) BR112015018360B1 (enExample)
CA (1) CA2897446A1 (enExample)
CL (1) CL2015002180A1 (enExample)
MX (1) MX2015010077A (enExample)
RU (1) RU2684112C2 (enExample)
UA (1) UA115683C2 (enExample)
WO (1) WO2014122468A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2746833C1 (ru) * 2020-08-03 2021-04-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Способ моделирования экспериментального воспаления легких у крыс
RU2863187C1 (ru) * 2025-10-10 2026-05-29 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ лечения тяжелых нозокомиальных инфекционно-воспалительных процессов, вызванных грамотрицательной флорой с приобретенной тотальной или субтотальной лекарственной резистентностью

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI690317B (zh) * 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法
HK1244791A1 (zh) 2015-03-31 2018-08-17 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
CA2984024A1 (en) 2015-09-16 2017-03-23 Xuanzhu Pharma Co., Ltd. .beta.-lactamase inhibitors and uses thereof
CN109310682A (zh) * 2016-06-17 2019-02-05 沃克哈特有限公司 抗菌组合物
SG11201901658PA (en) 2016-09-16 2019-04-29 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
US10434089B2 (en) 2017-01-25 2019-10-08 The Johns Hopkins University Avibactam and carbapenems antibacterial agents
PT3630111T (pt) 2017-05-08 2022-03-01 Entasis Therapeutics Inc Compostos e métodos de tratamento de infeções bacterianas
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP4272831A3 (en) 2018-08-09 2024-02-21 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN113413367B (zh) * 2021-08-16 2026-03-20 浙江尖峰药业有限公司 一种注射用阿维巴坦头孢甲肟复方粉针及其制备方法
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
WO2026104587A1 (en) 2024-11-13 2026-05-21 Adjutec Pharma As Cyclic boronic acid esters useful as adjuvants in the treatment of bacterial infections
CN119818504A (zh) * 2025-01-04 2025-04-15 重庆圣华曦药业股份有限公司 一种头孢哌酮和阿维巴坦的抗菌组合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178501B2 (en) * 2004-12-17 2012-05-15 Venus Remedies Limited Antibiotic combinations for providing total solution to the treatment of infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101074235B (zh) * 2006-05-15 2010-05-12 中国药品生物制品检定所 头孢硫脒醇水化合物及其制备方法
CN101245080A (zh) * 2007-02-14 2008-08-20 山东轩竹医药科技有限公司 含有吡唑并三唑的头孢菌素衍生物
AU2010229721A1 (en) * 2009-03-26 2011-10-06 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178501B2 (en) * 2004-12-17 2012-05-15 Venus Remedies Limited Antibiotic combinations for providing total solution to the treatment of infections

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEAUCAIRE G, et al., Phare study. Comparative study of combined cefepime-amikacin versus ceftazidime combined with amikacin in the treatment of nosocomial pneumonias in ventilated patients. Multicenter group study, Ann Fr Anesth Reanim. 1999 Feb;18(2):186-95.-. *
BRESSOLLE F ET AL, Еndotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia pharmacokinetics and absolute bioavailability, Antimicrobial agents and chemotherapy, 1992, vol. 36, no. 7, с. 1404-1411, . *
LEVASSEUR P. ET AL, In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates, Antimicrobial agents and chemotherapy, 2012, Mar, vol. 56, no. 3, , с. 1606 - 1608. *
LEVASSEUR P. ET AL, In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates, Antimicrobial agents and chemotherapy, 2012, Mar, vol. 56, no. 3, реферат, с. 1606 - 1608. BRESSOLLE F ET AL, Еndotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia pharmacokinetics and absolute bioavailability, Antimicrobial agents and chemotherapy, 1992, vol. 36, no. 7, с. 1404-1411, реферат. BEAUCAIRE G, et al., Phare study. Comparative study of combined cefepime-amikacin versus ceftazidime combined with amikacin in the treatment of nosocomial pneumonias in ventilated patients. Multicenter group study, Ann Fr Anesth Reanim. 1999 Feb;18(2):186-95.-реферат. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2746833C1 (ru) * 2020-08-03 2021-04-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Способ моделирования экспериментального воспаления легких у крыс
RU2863187C1 (ru) * 2025-10-10 2026-05-29 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ лечения тяжелых нозокомиальных инфекционно-воспалительных процессов, вызванных грамотрицательной флорой с приобретенной тотальной или субтотальной лекарственной резистентностью

Also Published As

Publication number Publication date
BR112015018360A2 (pt) 2017-07-18
UA115683C2 (uk) 2017-12-11
CL2015002180A1 (es) 2015-11-27
BR112015018360B1 (pt) 2022-03-22
CA2897446A1 (en) 2014-08-14
JP2016507547A (ja) 2016-03-10
JP6383367B2 (ja) 2018-08-29
WO2014122468A1 (en) 2014-08-14
EP2953626A1 (en) 2015-12-16
AU2014213795B2 (en) 2016-10-13
MX2015010077A (es) 2016-01-25
KR20150115761A (ko) 2015-10-14
US20150374673A1 (en) 2015-12-31
CN104994860A (zh) 2015-10-21
AU2014213795A1 (en) 2015-07-30
RU2015132369A (ru) 2017-03-13
CN110302203A (zh) 2019-10-08

Similar Documents

Publication Publication Date Title
AU2014213795B2 (en) Combination therapy for the treatment of nosocomial pneumonia
JP7245289B2 (ja) 細菌感染症の処置方法
US10376499B2 (en) Combination therapy for treatment of resistant bacterial infections
Qian et al. Synergy between baicalein and penicillins against penicillinase-producing Staphylococcus aureus
US11278622B2 (en) Ceftolozane antibiotic compositions
EP3003307B1 (en) Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections
HK1244798A1 (en) Combination therapy for treatment of resistant bacterial infections
JP2019151668A (ja) セフトロザン抗生物質組成物
RU2524665C2 (ru) Композиции и способы лечения, включающие цефтаролин
Dallow et al. Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes
Gómez-Junyent et al. In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm
US11129840B2 (en) Methods for identifying novel dosing regimens
HK40012654A (en) Combination therapy for the treatment of nosocomial pneumonia
Ito et al. Potent antibacterial activities of latamoxef (moxalactam) against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation
Kern Antibacterial agents
Guo et al. Novel MBLs inhibitors screened from FDA-approved drug library restore the susceptibility of carbapenems to NDM-1-harbouring bacteria
Bhalodi et al. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model
RU2377985C2 (ru) Средство для лечения инфекционных болезней, вызванных множественно-устойчивыми бактериями
Guilherme et al. Pharmacokinetic/pharmacodynamic target attainment of intravenous [beta]-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital
Henderson et al. Ceftobiprole

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant